Literature DB >> 8846020

Elevated concentrations of circulating intercellular adhesion molecule 1 (ICAM-1) and of vascular cell adhesion molecule 1 (VCAM-1) in HIV-1 infection.

L Gattegno1, M Bentata-Peyssare, S Gronowski, K Chaouche, F Ferriere.   

Abstract

The aim of this study was to determine whether elevated levels of circulating forms of the soluble adhesion molecules, Intercellular Adhesion Molecule-1 (cICAM-1), Vascular Cell Adhesion Molecule-1 (cVCAM-1) and E-Selectin (cE-Selectin) are observed in the sera of HIV-1 infected individuals as compared to healthy HIV seronegative adults and whether these elevated levels can be correlated with disease progression. Significantly elevated levels of cICAM-1-ranging from 184 to 1116 ng/ml with a mean of 617 ng/ml-and cVCAM-1-ranging from 653 to 3456 ng/ml with a mean of 1500 ng/ml-were observed in the sera of 29 HIV-1 infected individuals as compared to controls-ranging from 152 to 354 ng/ml with a mean of 248 ng/ml for cICAM-1 and from 328 to 792 ng/ml with a mean of 560 ng/ml for cVCAM-1 (P < 0.001). The serum concentrations of cE-Selectin of the HIV-1 infected individuals did not differ from those of the healthy controls. The elevated levels of cICAM-1, cVCAM-1 did not correlate with the CD4 count or the serum concentration of C-reactive protein. However, a significant correlation was observed between the serum concentrations of cVCAM-1 and those of neopterin. Since cICAM-1 as well as cVCAM-1 can interfere with adhesion events leading to immunological functions, it can be suggested that the high amounts of these circulating forms of adhesion molecules, when present in the sera of HIV-1 positive individuals, can further disturb the immune system of these patients. In addition, the present study also suggests that the seric concentrations of cVCAM-1 can be used as pronostic indicators.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8846020     DOI: 10.3109/15419069509081285

Source DB:  PubMed          Journal:  Cell Adhes Commun        ISSN: 1023-7046


  9 in total

1.  Variations in serum IL-7 and 90K/Mac-2 binding protein (Mac-2 BP) levels analysed in cohorts of HIV-1 patients and correlated with clinical changes following antiretroviral therapy.

Authors:  E C Darcissac; V Vidal; X De La Tribonniere; Y Mouton; G M Bahr
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

Review 2.  Expanding role of circulating adhesion molecules in assessing prognosis and treatment response in human immunodeficiency virus infection.

Authors:  Nikolaos V Sipsas; Petros P Sfikakis
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

3.  Endothelial activation biomarkers increase after HIV-1 acquisition: plasma vascular cell adhesion molecule-1 predicts disease progression.

Authors:  Susan M Graham; Nimerta Rajwans; Walter Jaoko; Benson B A Estambale; R Scott McClelland; Julie Overbaugh; W Conrad Liles
Journal:  AIDS       Date:  2013-07-17       Impact factor: 4.177

4.  Pentoxifylline reduces tumor necrosis factor-α and HIV-induced vascular endothelial activation.

Authors:  Linden Ann Green; Chul Kim; Samir K Gupta; Gangaraju Rajashekhar; Jalees Rehman; Matthias Clauss
Journal:  AIDS Res Hum Retroviruses       Date:  2012-05-08       Impact factor: 2.205

5.  Albuminuria is associated with elevated acute phase reactants and proinflammatory markers in HIV-infected patients receiving suppressive combination antiretroviral therapy.

Authors:  Pichaya O-charoen; Lishomwa C Ndhlovu; Louie Mar A Gangcuangco; Sheila M Keating; Philip J Norris; Roland C K Ng; Brooks I Mitchell; Cecilia M Shikuma; Dominic C Chow
Journal:  AIDS Res Hum Retroviruses       Date:  2014-12       Impact factor: 2.205

6.  Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial.

Authors:  Jason V Baker; Shweta Sharma; Birgit Grund; Adam Rupert; Julia A Metcalf; Mauro Schechter; Paula Munderi; Inka Aho; Sean Emery; Abdel Babiker; Andrew Phillips; Jens D Lundgren; James D Neaton; H Clifford Lane
Journal:  Open Forum Infect Dis       Date:  2017-11-28       Impact factor: 3.835

Review 7.  Clinical utility of biomarkers of endothelial activation and coagulation for prognosis in HIV infection: a systematic review.

Authors:  Susan M Graham; Regina Mwilu; W Conrad Liles
Journal:  Virulence       Date:  2013-06-24       Impact factor: 5.882

8.  Hemostatic Changes Associated With Increased Mortality Rates in Hospitalized Patients With HIV-Associated Tuberculosis: A Prospective Cohort Study.

Authors:  Saskia Janssen; Charlotte Schutz; Amy M Ward; Mischa A M Huson; Robert J Wilkinson; Rosie Burton; Gary Maartens; Katalin A Wilkinson; Joost C M Meijers; René Lutter; Martin P Grobusch; Graeme Meintjes; Tom van der Poll
Journal:  J Infect Dis       Date:  2017-01-15       Impact factor: 5.226

9.  Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.

Authors:  Rudolph L Gleason; Alexander W Caulk; Daniel Seifu; Ivana Parker; Brani Vidakovic; Helena Getenet; Getachew Assefa; Wondwossen Amogne
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.